Clinical relevance of brain volume measures in multiple sclerosis
Multiple sclerosis (MS) is a chronic disease with an inflammatory and neurodegenerative
pathology. Axonal loss and neurodegeneration occurs early in the disease course and may …
pathology. Axonal loss and neurodegeneration occurs early in the disease course and may …
The two sides of siponimod: evidence for brain and immune mechanisms in multiple sclerosis
Siponimod is a selective sphingosine 1-phosphate receptor subtype 1 (S1P1) and 5 (S1P5)
modulator approved in the United States and the European Union as an oral treatment for …
modulator approved in the United States and the European Union as an oral treatment for …
[HTML][HTML] Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis
Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …
Abnormal B‐cell cytokine responses a trigger of T‐cell–mediated disease in MS?
A Bar‐Or, L Fawaz, B Fan, PJ Darlington… - Annals of …, 2010 - Wiley Online Library
Objective To study antibody‐independent contributions of B cells to inflammatory disease
activity, and the immune consequences of B‐cell depletion with rituximab, in patients with …
activity, and the immune consequences of B‐cell depletion with rituximab, in patients with …
Rituximab in relapsing‐remitting multiple sclerosis: a 72‐week, open‐label, phase I trial
We evaluated the safety, tolerability, pharmacodynamics, and activity of B‐cell depletion with
rituximab in patients with relapsing‐remitting multiple sclerosis, receiving two courses of …
rituximab in patients with relapsing‐remitting multiple sclerosis, receiving two courses of …
Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis
J Smolders, M Thewissen, E Peelen, P Menheere… - PloS one, 2009 - journals.plos.org
Background In several autoimmune diseases, including multiple sclerosis (MS), a
compromised regulatory T cell (Treg) function is believed to be critically involved in the …
compromised regulatory T cell (Treg) function is believed to be critically involved in the …
Embedding electronic health records onto a knowledge network recognizes prodromal features of multiple sclerosis and predicts diagnosis
Objective Early identification of chronic diseases is a pillar of precision medicine as it can
lead to improved outcomes, reduction of disease burden, and lower healthcare costs …
lead to improved outcomes, reduction of disease burden, and lower healthcare costs …
Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating and neurodegenerative
disease affecting the central nervous system (CNS), often characterized by the accumulation …
disease affecting the central nervous system (CNS), often characterized by the accumulation …
Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis
M Krumbholz, I Meinl, T Kumpfel, R Hohlfeld, E Meinl - Neurology, 2008 - AAN Enterprises
Background: Natalizumab, a humanized anti-α4 integrin monoclonal antibody, reduces
relapses and disease progression in patients with multiple sclerosis (MS). Whereas its …
relapses and disease progression in patients with multiple sclerosis (MS). Whereas its …
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis
Objective: Neurodegeneration is now accepted as a pathologic hallmark of multiple
sclerosis (MS). We sought to discover whether CSF levels of neurofilament heavy chain …
sclerosis (MS). We sought to discover whether CSF levels of neurofilament heavy chain …